By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 194.13 |
| Change Today | $ -1.49 |
| % Change | -0.76 % |
| 52 Week High | $201.18 |
| 52 Week Low | $118.84 |
| Volume | 1,049,036 |
| Shares Issued | 146.80m |
| Market Cap | $28,498m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 16:00 | 100 @ $193.98 |
| 16:00 | 100 @ $193.98 |
| 15:59 | 100 @ $194.08 |
| 15:59 | 100 @ $194.08 |
| 15:59 | 144 @ $194.01 |
You are here: research